Next-Generation Cancer Immunotherapy Targeting Glypican-3

Cancer immunotherapy-targeted glypican-3 or neoantigens

(2018) Yasuhiro Shimizu et al.   CANCER SCIENCE

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape

(2018) David Pettitt et al.   MOLECULAR THERAPY

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy

(2018) Atsutaka Minagawa et al.   Cell Stem Cell

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

(2017) Wenpeng Li et al.   HUMAN GENE THERAPY

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

(2017) Takahiro Ishiguro et al.   Science Translational Medicine

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma

(2017) Zhiwu Jiang et al.   Frontiers in Immunology

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy

(2017) Mirjana Efremova et al.   Frontiers in Immunology

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma

(2017) Nobuhiro Tsuchiya et al.   OncoImmunology

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

(2017) Nobuhiro Tsuchiya et al.   OncoImmunology

The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy

(2016) James W.T. Toh et al.   Clinical Colorectal Cancer

T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells: Table 1.

(2016) Hiroaki Ikeda   INTERNATIONAL IMMUNOLOGY

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma

(2016) Kazuya Ofuji et al.   Oncotarget

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma

(2016) Shiro Suzuki et al.   OncoImmunology

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

(2016) Yu Sawada et al.   OncoImmunology

Notum deacylates Wnt proteins to suppress signalling activity

(2015) Satoshi Kakugawa et al.   NATURE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of glypican-3-derived long peptides activating both CD8+and CD4+T cells; prolonged overall survival in cancer patients with Th cell response

(2015) Mohammad A. Sayem et al.   OncoImmunology

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

(2015) Margaret K. Callahan et al.   Frontiers in Oncology

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma

(2014) Masafumi Ikeda et al.   CANCER SCIENCE

HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice

(2014) Yutaka Motomura et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

(2014) YU SAWADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma

(2013) Min Chen et al.   CLINICA CHIMICA ACTA

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide

(2013) YOSHITAKA TADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

(2013) Yu Sawada et al.   Human Vaccines & Immunotherapeutics

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

(2013) Shiro Suzuki et al.   Human Vaccines & Immunotherapeutics

Peptide intra-tumor injection for cancer immunotherapy

(2013) Daisuke Nobuoka et al.   Human Vaccines & Immunotherapeutics

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy

(2012) Daisuke Nobuoka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells

(2011) Toshiaki Yoshikawa et al.   CANCER SCIENCE

A Novel Mechanism of Sequestering Fibroblast Growth Factor 2 by Glypican in Lipid Rafts, Allowing Skeletal Muscle Differentiation

(2010) J. Gutierrez et al.   MOLECULAR AND CELLULAR BIOLOGY

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

(2009) Hirofumi Shirakawa et al.   CANCER SCIENCE

Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface

(2008) Alexandra Traister et al.   BIOCHEMICAL JOURNAL

Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer

(2008) T. Ishiguro et al.   CANCER RESEARCH